Turn Therapeutics (TTRX) Interim CFO Zuraiz Chaudhary Receives 80,000-Share Award

What Happened Zuraiz Chaudhary, Interim Chief Financial Officer (also VP of Finance & Chief Accounting Officer) of Turn Therapeutics (TTRX), was granted a derivative award covering 80,000 shares on April 1, 2026. The Form 4 reports the acquisition as an award (transaction code A) with a reported price of $0.00 — this reflects an option/award grant rather than an open-market purchase or sale. No immediate cash value or proceeds were reported.

Key Details

• Transaction date: April 1, 2026; Form 4 filed April 3, 2026 (filed within the standard 2-business-day window).
• Instrument/transaction: Award (derivative) covering 80,000 shares; reported price $0.00.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: Vesting schedule — 25% vests on the first anniversary of the grant; the remaining 75% vests ratably over the following 36 months, subject to continued employment and the Issuer's 2025 Omnibus Incentive Plan.
• Remarks: Reporting person holds the roles of Interim CFO, VP Finance & Chief Accounting Officer.

Context This was a typical equity award to an executive (not an open-market buy or sale). Such grants are commonly used for compensation and retention and generally do not indicate immediate buying or selling pressure — shares (or the economic benefit) will only accrue as the awards vest and any options are exercised according to plan terms.